Frontlight ResearchEarly access
Information, not a decision
Gastric and oesophageal cancer: tumour board sheet
Dated public registry data. It contains no treatment recommendation.
Data as of 19 Nov 2026
Open trials (1484)
Phase 3 trials that ended in the last 90 days
| Registry ID | Ended | Trial | Status |
|---|---|---|---|
| NCT05568095 | 28 Aug 2026 | A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body | Completed |
Guidelines
Links only: read the guideline itself.
- ESMO Clinical Practice Guidelinesesmo.org
- NCCN Guidelinesnccn.org
- [Expert consensus on pathological evaluation of esophageal squamous cell carcinoma after neoadjuvant therapy (2026 version)].pubmed.ncbi.nlm.nih.gov
- Position statement from the Asociación Mexicana de Gastroenterología on the early detection and timely referral of gastrointestinal cancer (esophagus, stomach, and colon) in primary care.pubmed.ncbi.nlm.nih.gov
Made from the public data of Frontlight Research. Source: ClinicalTrials.gov. 19 Nov 2026
https://frontlightresearch.com/en/doctor/gastric-and-esophageal-cancer/tumor-board